Management of Elevated Homocysteine in Older Men

Causes of Moderate Hyperhomocysteinemia (15‑30 μmol/L)

Metabolic vitamin B12 deficiency is present in ≈ 10.6 % of older adults and in ≈ 18 % of individuals > 80 years, making it a common contributor to elevated homocysteine. 2
Folate deficiency is less frequent in regions with mandatory folate fortification of foods. 1
Age‑related decline in renal function is a major driver of homocysteine accumulation in the elderly. 3
Inadequate dietary intake of B‑vitamins can raise homocysteine levels. 1
The MTHFR 677TT genotype impairs folate metabolism and predisposes to higher homocysteine concentrations. 1

Measure fasting total homocysteine and classify severity: moderate 15‑30 μmol/L, intermediate 30‑100 μmol/L, severe > 100 μmol/L. 1
Assess serum vitamin B12, folate, and methylmalonic acid; a B12 level < 258 pmol/L together with elevated homocysteine or methylmalonic acid indicates metabolic B12 deficiency even when B12 appears “normal.” 2
Review current medications for agents that interfere with B12 or homocysteine metabolism (e.g., metformin, PPIs). 1

Prioritize correction of the underlying cause (e.g., B12 deficiency, renal impairment, dietary insufficiency) before considering homocysteine‑lowering therapy. 1
Oral vitamin B12 supplementation at 0.02‑1 mg/day (20‑1000 µg/day) yields an additional ≈ 7 % reduction in homocysteine beyond folate alone. [1][4]
Prefer methylcobalamin or hydroxycobalamin over cyanocobalamin, especially in patients with renal dysfunction. 2
B12 supplementation is safe, inexpensive, and at minimum not harmful. 1

Large randomized trials in populations with adequate folate intake have not demonstrated any reduction in cardiovascular mortality or major cardiovascular events from B‑vitamin (including B12) supplementation. 3
In folate‑fortified regions (e.g., North America), pharmacologic B‑vitamin supplementation provides no additional vascular benefit beyond that achieved by dietary intake. [3][4]
Moderate‑quality evidence indicates that B‑vitamin supplementation may reduce ischemic stroke risk by ~43 % in non‑fortified populations, representing a class 2a recommendation for stroke prevention. 2

Aggressive lipid‑lowering with statin therapy remains the evidence‑based strategy for reducing cardiovascular mortality in patients with hypercholesterolemia, unlike homocysteine‑lowering approaches. 1